WEE1i-ATRi combination therapy: a promising low-dose treatment for CCNE1-amplified gynecologic cancers

CCNE1 amplification is an oncogenic driver for many gynecologic cancers and is associated with poor patient outcomes. In this issue, Xu et al.1 identify a combination therapy that is responsive to high CCNE1-copy number ovarian and endometrial cancers using PDX models. CCNE1 amplification is an onco...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cell reports. Medicine 2021-09, Vol.2 (9), p.100402-100402, Article 100402
Hauptverfasser:	Goehring, Liana, Huang, Tony T.
Format:	Artikel
Sprache:	eng
Schlagworte:	Cyclin E Endometrial Neoplasms - drug therapy Female Humans Oncogene Proteins - genetics Ovarian Neoplasms - drug therapy Preview
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	CCNE1 amplification is an oncogenic driver for many gynecologic cancers and is associated with poor patient outcomes. In this issue, Xu et al.1 identify a combination therapy that is responsive to high CCNE1-copy number ovarian and endometrial cancers using PDX models. CCNE1 amplification is an oncogenic driver for many gynecologic cancers and is associated with poor patient outcomes. In this issue, Xu et al.1 identify a combination therapy that is responsive to high CCNE1-copy number ovarian and endometrial cancers using PDX models.
ISSN:	2666-3791 2666-3791
DOI:	10.1016/j.xcrm.2021.100402